Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-Infiltrating Lymphocytes (Autologous) (None)
- Target
- None
- Molecular classification
- Cellular Therapy, T lymphocytes, B lymphocytes
01
Overview
Tumor-infiltrating lymphocytes (TILs) are a subset of white blood cells, primarily T cells and B cells, that have migrated into tumor tissue. Autologous TIL therapy involves isolating TILs from a patient's own tumor, expanding them ex vivo, and reinfusing them back into the patient to enhance anti-tumor immunity. It is used as a form of personalized immunotherapy, with efficacy demonstrated in advanced solid tumors, particularly metastatic melanoma.
02
Mechanism of action
Adoptive cell transfer immunotherapy: ex vivo expansion and reinfusion of patient's own tumor-reactive lymphocytes to target and kill tumor cells.
03
Biological functions
Adaptive immune responseAnti-tumor immunityCytotoxicityTargeted cell death
04
Disease associations
Cancer
05
Safety considerations
Toxicities related to high-dose IL-2 administrationImmune-related adverse eventsLack of response in some patientsPotential for cytokine release syndrome
06
Interacting drugs
Interleukin-2 (IL-2)
3 more in the full profile.
07
Biomarkers
TIL abundance (prognostic)TIL activity profile (prognostic)
Beyond the preview
Go deeper on Tumor-Infiltrating Lymphocytes (Autologous) (None).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor-Infiltrating Lymphocytes (Autologous) (None).